NASDAQ:VIVS VivoSim Labs Q1 2026 Earnings Results & Report $0.18 0.00 (-0.61%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more. VivoSim Labs reported Q1 2026 earnings on August 12, 2025. The company reported EPS of -$1.14, while revenue was $0.04 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateAugust 12, 2025TimeAfter Market Closes VivoSim Labs EPS ResultsActual EPS-$1.14Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AVivoSim Labs Revenue ResultsActual Revenue$0.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile VivoSim Labs Q1 2026 Earnings FAQ Did VivoSim Labs beat earnings estimates for Q1 2026? VivoSim Labs (NASDAQ:VIVS) reported earnings of -$1.14 per share for Q1 2026. The report was announced on Tuesday, August 12, 2025. What was VivoSim Labs' revenue for Q1 2026? VivoSim Labs reported revenue of $0.04 million for Q1 2026. VivoSim Labs Earnings HeadlinesVivoSim Labs Highlights FDA Pathway For Human-Based Safety Testing;Stock UpOctober 7, 2026 | rttnews.comVivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsOctober 7, 2026 | financialpost.comFTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may be a bid to reset the US dollar. Porter Stansberry says the meeting, attended by figures like Elon Musk, Jensen Huang and Larry Fink, connects to a 13-nation pact designed to cut China out of a massive investment wave.October 12 at 1:00 AM | Porter & Company (Ad)VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsOctober 7, 2026 | globenewswire.comVivoSim Labs Shareholders Approve Governance and Capital ChangesOctober 6, 2026 | tipranks.comAnalyzing iSpecimen (NASDAQ:ISPC) & VivoSim Labs (NASDAQ:VIVS)October 2, 2026 | americanbankingnews.comSee More VivoSim Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VivoSim Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VivoSim Labs and other key companies, straight to your email. Email Address About VivoSim LabsOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.View VivoSim Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
